United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag ...

United Therapeutics announced its phase 3 study for ralinepag, a once-daily oral drug for pulmonary arterial hypertension (PAH), met its primary endpoint, reducing clinical worsening events by 55% versus placebo. The results, published in The Lancet, support the company's New Drug Application submitted to the FDA.

This Wire brief sits within Fusion42's coverage of Drug Discovery. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.